Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.33 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25100553 | 0.84 | FDFT1 (0.36) | FDFT1KMT2ACHRNB2CHRNA4 | |
| SCHEMBL13010773 | 0.82 | TSHR (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL5199624 | 0.80 | GCK (0.46) | — | |
| SCHEMBL5198999 | 0.79 | NR1H2 (0.33) | — | |
| SCHEMBL10263431 | 0.78 | TNKS (0.34) | TNKSPARP1TNKS2OGAMEN1 | |
| SCHEMBL1554553 | 0.78 | MBOAT4 (0.33) | KMT2ACHRNB2CHRNA4 | |
| SCHEMBL23956200 | 0.78 | FDFT1 (0.33) | FDFT1CHRNB2CHRNA4 | |
| SCHEMBL24129962 | 0.78 | PDE2A (0.38) | KMT2ASMOCHRNB2CHRNA4CDK1 | |
| SCHEMBL5199607 | 0.78 | HRH3 (0.35) | FDFT1HRH3 | |
| SCHEMBL14335593 | 0.77 | MEN1 (0.38) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20250382300-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-12-18 | — | — | US | disclosed |
| EP-3883576-B1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4655304-A1 | MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | Yuhan Corporation (KR) | 2025-12-03 | — | — | EP | disclosed |
| US-12466831-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-3883575-B1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4619101-A1 | NOVEL PYRROLO[1,2-d][1,2,4]TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS | Neurosterix Pharma Sàrl (CH) | 2025-09-24 | — | — | EP | disclosed |
| US-12414952-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250171447-A1 | ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-05-29 | — | — | US | disclosed |
| WO-2004048377-A2 | METHOD OF PREPARING INHIBITORS OF PHOSPHODIESTERASE-4 | MERCK & CO., INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004045508-A2 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO., INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| US-6743802-B2 | ASTHMA THERAPY; ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2004-06-01 | — | — | US | disclosed |
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
| EP-1397359-A1 | 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-03-17 | — | — | EP | disclosed |
| US-6677351-B2 | USEFUL IN TREATMENT OF ASTHMA AND INFLAMMATION | MERCK FROSST CANADA & CO. (CA) | 2004-01-13 | — | — | US | disclosed |
| US-20030114478-A1 | Alkyne-aryl phosphodiesterase-4 inhibitors | MERCK CANADA INC. (CA) | 2003-06-19 | — | — | US | disclosed |
| US-20030096829-A1 | 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-05-22 | — | — | US | disclosed |
| WO-2003018579-A1 | ALKYNE-ARYL PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-03-06 | — | — | WO | disclosed |
| WO-2002094823-A1 | 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382300-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2B, ADORA2A, ADORA3 | TNKS 979/4885PARP1 818/4885TNKS2 686/4885 |
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | PDE4B, PDE4A, PDE5A | TNKS 693/4885PARP1 837/4885TNKS2 658/4885 |
| US-20250171447-A1 | ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF | ADORA2A, ADORA2B, ADORA1 | TNKS 2257/4885PARP1 1068/4885TNKS2 2183/4885 |
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLK, POLH | TNKS 193/4885PARP1 232/4885TNKS2 259/4885 |
| US-20030096829-A1 | 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE7A | TNKS 282/4885PARP1 199/4885TNKS2 509/4885 |
| US-12466831-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2A, ADORA2B, ADORA3 | TNKS 996/4885PARP1 855/4885TNKS2 609/4885 |
| US-20030114478-A1 | Alkyne-aryl phosphodiesterase-4 inhibitors | PDE4A, PDE3B, PDE4B | TNKS 1072/4885PARP1 1089/4885TNKS2 1651/4885 |
| US-12414952-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2B, ADORA2A, ADORA3 | TNKS 878/4885PARP1 719/4885TNKS2 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.